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The p53 gene family members p53, p73, and p63 display several isoforms derived from 
the presence of internal promoters and alternative splicing events. They are structural 
homologs but hold peculiar functional properties. p53, p73, and p63 are tumor sup-
pressor genes that promote differentiation, senescence, and apoptosis. p53, unlike p73 
and p63, is frequently mutated in cancer often displaying oncogenic “gain of function” 
activities correlated with the induction of proliferation, invasion, chemoresistance, and 
genomic instability in cancer cells. These oncogenic functions are promoted either by the 
aberrant transcriptional cooperation of mutant p53 (mutp53) with transcription cofactors 
(e.g., NF-Y, E2F1, Vitamin D Receptor, Ets-1, NF-kB and YAP) or by the interaction 
with the p53 family members, p73 and p63, determining their functional inactivation. 
The instauration of these aberrant transcriptional networks leads to increased cell 
growth, low activation of DNA damage response pathways (DNA damage response and 
DNA double-strand breaks response), enhanced invasion, and high chemoresistance 
to different conventional chemotherapeutic treatments. Several studies have clearly 
shown that different cancers harboring mutant p53 proteins exhibit a poor prognosis 
when compared to those carrying wild-type p53 (wt-p53) protein. The interference of 
mutantp53/p73 and/or mutantp53/p63 interactions, thereby restoring p53, p73, and 
p63 tumor suppression functions, could be among the potential therapeutic strategies 
for the treatment of mutant p53 human cancers.
Keywords: p53 gene family members, gain of function, homology, isoforms, protein–protein interaction, target 
genes, apoptosis, differentiation
inTRODUCTiOn
p53, p73, and p63 proteins belong to a family evolutionarily conserved in animals. They derive from 
an ancestral gene by duplication and consequent divergence of the original sequence. Functional 
and phylogenetic analyses reveal that the founding member was p63, followed by p73 and lastly p53 
(1–4). In fact, at the sequence level, p63 and p73 display elevated homology to each other, more than 
to p53 (5–9). Generally, the protein structure consists of a central DNA-binding domain (DBD) (core 
domain) that binds to response elements of target genes (10–14). The N-terminal transcription-
activation domain (TAD) is the binding-site for positive (e.g., p300/CBP and TAFII40/60) or nega-
tive regulators (e.g., MDM2 and MDMX) of gene transcription (15). The C-terminal oligomerization 
domain (OD) is subject to splicing and post-translational modifications, and it has been shown to 
influence DNA binding and transcriptional activity of the p53 family members (16) (Figure 1).
FiGURe 1 | p53, p73, and p63 isoforms obtained by the presence of internal promoters in the sequence (Δn isoforms) and by alternative splicing. The 
N-terminal transcription-activation domain (TAD) contains two subdomains (AD1 and AD2) and is the binding-site for regulators of gene transcription; in p63 and p73 
proteins, the C-terminal transactivation inhibitory domain (TID) binds to the TAD preventing constitutive transcriptional activity. The Proline-rich sequence recognition 
domains (PRD) can recognize proline-rich motifs of interacting proteins and has been reported to be essential for the induction of apoptosis driven by p53, p73 and 
p63. The DNA-binding domain (DBD) is responsible for the binding to DNA consensus of target genes and the oligomerization domain (OD) enables monomers 
assembly in active oligomers. The sterile alpha motif domain (SAMD) of p63 and p73 is arranged in a small five-helix bundle and is involved in protein–protein 
interactions. The basic region (BR) in the C-terminal of p53 is involved in the control of the DNA binding affinity.
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The human TP53 gene (Chr.17p13.1) is about 20 kb, contains 
11 exons and encodes for the tumor suppressor p53 protein 
known as “the guardian of the genome” (17–28). This protein 
was discovered in 1979 (29–31). p53 is not only able to act as 
a transcription factor but it is also involved in transcription-
independent response, such as apoptosis (32). TP53 is the most 
frequently mutated gene in human cancers (33–36). It is mostly 
affected by missense mutations often in the DBD of the protein 
(37–39). An increasing number of p53-mutated proteins can be 
distinct in either conformational mutants (when the mutations 
change the tridimensional structure of the protein) or in DNA-
contact defective mutants (when the mutations affect the region 
designate for the binding to the DNA) (36, 40). These alterations 
lead to the inability of mutant p53 proteins to fully recognize 
the DNA consensus sequence for wt-p53 or alter the functional 
interaction with pro-apoptotic partners, such as WW domain-
containing oxidoreductase WOX1 (WWOX). The WWOX/
wt-p53 complex is demonstrated to induce apoptosis synergisti-
cally and WWOX is essential for p53 activation and apoptosis 
induction (41). Strikingly, some of the p53-mutated proteins 
acquire new oncogenic functions [gain of function (GOF)] that 
strongly contribute to increasing cell proliferation, invasion, 
angiogenesis, genomic instability and chemoresistance in human 
cancers. These functions are often promoted by the interaction 
with sequence-specific transcription factors and the consequent 
activation/repression of specific target genes diverse from those 
recruited by wt-p53 (15, 42–58).
The TP73 gene (Chr.1p36.33) is about 65  kb and contains 
14 exons. It was discovered in 1997 (59) and similar to its fam-
ily members, plays an important role at different regulatory 
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checkpoints of the cell cycle (60). However, p73 shows a peculiar 
function in neuronal differentiation, not shared with p53 (8, 
61). p73 is rarely affected by mutation in cancer progression (62, 
63) but its expression is deregulated in several human tumors, 
such as in hepatocellular carcinoma (64), neuroblastoma (65), 
lung cancer (62), prostate cancer (66) and colorectal carcinoma 
(67). p73 shares many p53 tumor suppression functions through 
the activation of the p53-target genes (p21waf1, Bax, PUMA, 
NOXA, IGF-BP3 and Cyclin G), resulting in the control of cell 
proliferation, differentiation, development and induction of 
apoptosis (68–79). Moreover, p73, like p53, can interact with 
the tumor suppressor WWOX and trigger apoptosis (80, 81). 
Cells exposure to DNA-damaging agents (e.g., γ-radiation and 
cisplatin) induces p73 protein activation and accumulation with 
consequent induction of DNA damage response (DDR), growth 
arrest and apoptosis (76, 82–88).
The TP63 gene (Chr.3q27–29) is approximately 65 kb and con-
tains 15 exons (89, 90). Like p73, p63 can activate many p53-target 
genes in response to oncogenic stress or DNA damage (Bax, 
14-3-3σ, p53AIP1, IGF-BP3, p21waf1 and cyclin G), it controls cell 
proliferation, apoptosis, differentiation and development, and 
shows a tissue-specific localization (79, 91–94). p63 knockout 
mice exhibit a lethal phenotype soon after birth. They suffer from 
epithelial abnormalities, concerning skin, glands, teeth and hair 
follicles (95). Mutations of p63 are extremely rare in malignancies 
in contrast to p53 mutations. However, alterations in p63 expres-
sion patterns play an important role in tumorigenesis (96–98).
The full-length forms of p73 and p63 can also bind to YAP protein 
in response to DNA-damaging agents and activate pro-apoptotic 
target genes, such as Bax and p53AIP1 (78, 87, 99–101). Thus, both 
p73 and p63 can promote p53-independent apoptosis (102).
PROTein STRUCTURe AnD ReSPeCTive 
iSOFORMS OF THe p53 FAMiLY Gene 
MeMBeRS
p53 family gene members show a high degree of similarity in the 
exon/intron organization and share a similar modular protein 
structure previously described (Figure 1). p73 and p63 proteins 
display 22–29% of homology in the TAD domain, 63% in the 
DBD, and 42% in the OD of p53. Furthermore, critical residues 
in the DBD, involved in the folding and binding to target DNA 
sequences, are strictly conserved (22, 103–106). Moreover, p73 
and p63 share a sterile alpha motif domain (SAMD) and a trans-
activation inhibitory domain (TID); p53, p63, and p73 contain 
also a proline-rich sequence recognition domain (PRD). p53 also 
shows an additional basic region (BR) in the C-terminal tail (16, 
107, 108) (Figure 1).
p53 protein displays nine isoforms obtained by the presence of 
cryptic internal promoters and by alternative splicing. The result 
is the presence of potentially transcript inert isoforms N-terminal 
deleted (ΔN) and with various C-terminal tails (108) (Figure 1). 
The same mechanisms occur for p73 and p63: p73 displays 14 iso-
forms and p63 exhibits 10 isoforms (59, 90, 109–117) (Figure 1). 
The N-terminal truncated isoforms ΔNp73 and ΔNp63 are 
highly expressed in the development and display an oncogenic 
dominant-negative function to p73 and p63 full-length (TAp73 
and TAp63, respectively) and wt-p53 (39, 114, 118–124).
mutp53, p73, AnD p63 PROTein 
inTeRACTiOnS in CAnCeR
It was observed that human tumor-derived p53 mutants could 
bind p73α interfering with its transcriptional activity and imped-
ing apoptosis induction (125, 126). Strano et  al. (127) demon-
strate that p53 mutants (p53R175H and p53D281G) associate 
with four p73 isoforms in vitro and in vivo (p73α, p73β, p73γ and 
p73δ). The interactions occur also in physiological conditions in 
breast cancer cell lines (T47D and SKBR3) and require the DBD 
of mutp53 and the DBD and OD domains of p73 isoforms. Marin 
et al. (126) show that the interaction between mutp53 and p73α 
or p73β is also governed by a polymorphism at the codon 72 of 
the p53 mutant proteins (e.g., mutp53R175H and mutp53V143A) 
that encode for Arginine (R) or Proline (P). Particularly, p53 
mutants with R72 polymorphism favor binding to p73 more 
than the P72 polymorphism determining poor response to 
therapy and poor prognosis in patients (128, 129). Thus, either 
the type of p53 mutation and 72R/P polymorphism determine 
mutp53/p73 interaction (126). The mutp53/p63 interaction, 
in vitro and in tumor cells, is also reported (126). Gaiddon et al. 
(130) demonstrate that p73α, p73β, p73γ, and p73δ can interact 
with overexpressed or endogenous p53 mutants (R175H, H179R, 
Y220C, R248W and R273H) and demonstrate that p53 mutants 
(R175H, Y220C and R248W) can bind to p63α and p63γ. Low-
affinity interactions are observed between mutp53R175H and 
ΔNp63α or ΔNp63γ. Moreover, they observe that the interaction 
between p73α and p63α or ΔNp63α is more efficient if p73α is 
mutated (R292H). Gaiddon et al. (130) confirm that p53 mutants 
require the DBD domain for the interaction with p73 or p63. 
Moreover, p53 mutants deleted in several regions, resulting in 
conformational changes of the DBD, are still able to bind p73 
and p63. Thus, also the wild-type DBD of mutp53 can interact 
with p73 or p63 if it is in a mutant conformation (130, 131). It 
is also demonstrated that the heat shock protein HSC70 binds 
those p53 mutants that interact with p73 but not wt-p53 (130, 
132), thus, other determinants could affect p53/p73 interaction 
(130). Strano et  al. (46) demonstrate that, under physiological 
conditions, mutp53 interacts with p63α and p63γ in T47D and 
HaCat cells and in H1299 cells overexpressing mutp53R273H or 
mutp53R248W. They observe direct interactions mediated by the 
DBDs of mutp53 and p63. Mutp53D281G displays a GOF activ-
ity, it slightly binds to p73 but does not interact with p63 (46, 126, 
127, 133). Moreover, mutp53D281G mutated in the TAD loses 
its GOF, suggesting that the TAD exerts an important oncogenic 
role in the GOF of this p53 mutant (15, 134, 135). Santini et al. 
(136) provide biochemical evidence on the interaction between 
mutp53R175H and p73. They use atomic force spectroscopy 
(AFS) (137, 138) and surface plasmons resonance (SPR) (139, 
140), identifying a high interaction force and a dissociation equi-
librium constant typical for specific bounds. They do not observe 
any interactions between wt-p53 and p73 (136), confirming the 
lack of in vivo evidence for the formation of wt-p53/p73 protein 
FiGURe 2 | The presence of mutant p53 moves the tumor suppressor functions of p73 and p63 to an oncogenic outcome through binding and 
inactivating p73 and p63 transcriptional activity. The development of new anticancer strategies, such as increasing p73/p63 activities and employing molecules 
that interfere with mutantp53/p73 and/or mutantp53/p63 interactions [e.g., the molecule p53 reactivation and induction of massive apoptosis (PRIMA-1Met), short 
interfering mutp53 peptides (SIMPs), NSC59984 and Aptamers], could restore the p53 family’s tumor suppressor functions.
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complex. Weissmueller et al. (141) confirm that mutant p53 is able 
to bind p73 and this interaction results in the reduction of p73/
NF-Y inhibitory complex in pancreatic ductal adenocarcinoma. 
This complex displays a tumor suppressor function repressing the 
oncogenic platelet-derived growth factor receptor b (PDGFRb) 
that promotes cell invasion and metastasis. Therefore, indirectly, 
mutant p53 promotes PDGFRb expression disassembling the 
inhibitory p73/NF-Y complex. Liu et al. (142) show that TopB1 
protein promotes mutp53/NF-Y and mutp53/p73/p63 complex 
formation, inducing chemoresistance and proliferation in cancer 
cells. Wang and Fersht (143) describe the aggregation kinetics 
of mutant p53 that co-aggregate in tetramers by trapping also 
wt-p53, p73, and p63 proteins in the complex. It is worth to men-
tion the role of MDM2 in the mutp53, p63, and p73 interplay: a 
recent work shows that MDM2, a negative regulator of wt-p53, 
competes with p63 for binding to mutp53R175H and in this way 
p63 activity is restored; but, on the other hand, MDM2 forms a 
trimeric complex with p73 and mutp53R273H strongly inhibiting 
p73 function (144). All these are clear examples of how different 
mutations in p53 protein could determine distinct protein–pro-
tein interactions and cell responses.
FUnCTiOnAL iMPLiCATiOn OF  
mutp53/p73/p63 PROTein  
inTeRACTiOnS in CAnCeR
Knockout mice for p53−/−, p73−/− and p63−/− highlight the major 
physiological roles of these proteins (96), suggesting pivotal 
functions in the development of nervous and immune systems 
(mediated by p73), in skin and limb development (mediated 
by p63) and in tumor suppression (mediated primarily by p53) 
(111, 145–148).
The role of p73 and p63 in tumorigenesis (p53-dependent or 
independent) is controversial. In many tumors, these proteins are 
downregulated, in others they are overexpressed or their genes are 
amplified. This apparent incongruence is mainly due to the differ-
ent isoforms, tissue-specific localization and functions exerted by 
these proteins (121, 130, 149, 150). The decisive effect depends on 
the ratio TA/ΔN of p73 and p63 isoforms, p73/p63 interactions and 
p73/p63 binding to the promoters of p53-target genes. (151–155).
The status of p53 in cancer cells is a determining factor in the 
response to anticancer treatments (156–159). Some of the GOF 
activities mediated by mutp53 are related to the interaction, and 
consequent inactivation, of p73 and p63 (Figure 2). For example, 
the increase in chemoresistance to etoposide or cisplatin might 
involve the mutp53-dependent inactivation of p73-induced 
cell death (127, 128, 160–162). Importantly, in the presence of 
mutant p53 is observed a marked reduction of the transcriptional 
activity of p73α, p73β, p73γ and p73δ on the p21waf1 promoter 
(127). Gaiddon et  al. (130) show that the interaction between 
p73 and p53 mutants (R175H, Y220C and R283H) reduces p73 
transactivation of the p21waf1 promoter, highlighting the correla-
tion between the capability of p53 mutants to interact with p73 
and inhibit its transcriptional activity. Similar results are obtained 
for those p53 mutants that bind to p63α and p63γ reducing p63 
activation of the p21waf1 promoter (130). When mutp53 binds 
to the OD domain of p73, it causes the functional inhibition of 
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p73, impairing the interactions with other modulators (162). 
Furthermore, when mutp53 binds to the DBD of p73, it provokes 
a physical sequester of p73 from the consensus sequences on the 
target genes (127, 163, 164). Similarly, mutp53/p63 interaction 
results in p63 impairment of the transcriptional activation of its 
target genes (Bax, p21waf1, Cyclin G, 14-3-3σ and p53AIP1) (46). 
The formation of mutp53/p63 complex is also directly related 
to promoting cell invasion and metastasis in several cancer cell 
lines through mutp53-dependent inactivation of TAp63 tumor 
suppression functions (165–167).
In the past, many studies were dedicated to restoring the wild-
type activity of the mutant p53 proteins (168). A great number 
of small molecules, aiming to restore and stabilize the original 
DBD conformation of p53, have been developed, such as p53 
reactivation and induction of massive apoptosis (PRIMA-1) and 
maleimide-derived molecule MIRA-1. These compounds showed 
great promise when tested in cancer cell lines, demonstrating the 
induction of apoptotic processes (169–172). Unfortunately, the 
application of these molecules in the clinical practice is far off 
because the increased activity of p53 subjects non-cancerous cells 
to apoptosis induction. Further research is needed to minimize 
the level of cell toxicity (173). Another approach, proposed by Di 
Agostino et al. (174), refers to the disassembling of the mutp53/
p73 complex using short interfering mutp53 peptides (SIMPs) 
(10–15 residues) that compete specifically with p73 for the bind-
ing of mutp53 to the DBD. This results in releasing p73 from the 
complex, activating apoptosis and rescuing cells from chemosen-
sitivity. Notably, SIMPs have no cytotoxic effects on cells carrying 
wt-p53 proteins (174).
PRIMA-1MET (APR-246, developed by APREA), a compound 
very similar to PRIMA-1 but much more active at low dosage, is 
discovered to restore mutant p53 (R273H and R175H) activity 
in vitro and in vivo (170, 175). Interestingly, PRIMA-1MET not only 
restores the pro-apoptotic function of p53 but is also involved 
in activating downstream target genes of the p53 family (176, 
177). PRIMA-1MET alone and in combination with chemothera-
peutic drugs are effective to induce apoptosis in vivo (178, 179). 
PRIMA-1MET has also successfully completed a Phase I clinical 
trial, showing a promising efficacy (https://www.clinicaltrials.
gov/ct2/show/NCT00900614). This molecule seems to lead to 
the formation of covalent adducts on mutant p53R175H and 
p53R273H proteins, but the exact mechanism of action has yet to 
be fully elucidated (180). Moreover, recently it is discovered that 
a small molecule, NSC59984, can restores wt-p53 signaling via 
p73 activation and induces p73-dependent cell death in colorectal 
cancer cells, without evident toxicity toward normal cells (181).
COnCLUSiOnS
Flores et  al. (164) demonstrated that wt-p53, p73 and p63 are 
recruited onto regulatory regions of the p53-target genes induc-
ing growth arrest, differentiation, senescence and apoptosis 
(Figure 2). Despite this, the DBD of mutp53, previously regarded 
as “dead domain” since it could not bind to the wt-p53 binding 
site of its target genes, acquires a new protein–protein interac-
tion function sequestering and inactivating tumor suppression 
proteins, including the family members p73 and p63. This mecha-
nism contributes to the GOF activity of mutp53 (9).
FUTURe PeRSPeCTiveS
The precise tackling of GOF activity of mutant p53 might lead 
to the discovery of drugs with broad anticancer effects. As far as 
our knowledge on the molecular mechanisms governing mutant 
p53 oncogenic activities advances, we have learned that mutant 
p53 proteins are not a single entity but a protein family with 
high intrinsic complexities. Since mutant p53 is a partner of 
oncogenic multi-protein complexes, one way to severely defeat 
its pro-tumorigenic activity may reside in the specific target-
ing of its key cooperative partners. Along this line of evidence, 
agents that increase p73 and/or p63 activity promoting chemo-
sensitivity could represent a promising strategy to treat tumors 
harboring mutant p53 proteins (122, 182, 183) (Figure  2). It 
could be useful to develop and validate reagents that interfere 
with mutp53/p73 and mutp53/p63 interactions restoring p53, 
p73, and p63 tumor suppression functions. NSC59984, PRIMA-
1MET, SIMPs and peptide aptamers, which bind specifically to 
mutant p53, could be a potent strategy in cancer therapy for 
these tumors (174, 181, 184) (Figure 2). Undoubtedly, greater 
knowledge must be acquired regarding the determinants of 
these oncogenic multi-protein complexes in order to design and 
pave novel therapeutic strategies to successfully treat mutant 
p53 human tumors.
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